References
- Chabner B, Roberts Jr TG. Chemotherapy and the war on cancer. Nat. Rev. Cancer5, 65–72 (2005).
- Crom WR. Methotrexate. In: A Clinician’s Guide to Chemotherapy Pharmacokinetics and Pharmacodynamics. Grochow LB, Ames MM (Eds). Williams & Wilkins, MD, USA, 311–330 (1998).
- Messmann RA, Allegra CJ. Antifolates. In: Cancer Chemotherapy and Biotherapy. Chabner BA, Longo DL (Eds). Lippincott Williams & Wilkins, PA, USA, 139–184 (2001).
- Buchen S, Ngampolo D, Melton RG et al. Carboxypeptidase G2 rescue in patients with methotrexate intoxication and renal failure. Br. J. Cancer92, 480–487 (2005).
- Fukuhara K, Ikawa K, Morikawa N, Kumagai K. Population pharmacokinetics of high-dose methotrexate in Japanese adult patients with malignancies: a concurrent analysis of the serum and urine concentration data. J. Clin. Pharm. Ther.33, 677–684 (2008).
- Trevino LR, Shimasaki N, Yang W et al. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects. J. Clin. Oncol.27, 5972–5978 (2009).
- Lopez-Lopez E, Martin-Guerrero I, Ballesteros J et al. Polymorphisms of the SLCO1B1 gene predict methotrexate-related toxicity in childhood acute lymphoblastic leukaemia. Pediatr. Blood Cancer57, 612–619 (2011).
- Crews KR, Liu T, Rodriguez-Galindo C et al. High-dose methotrexate pharmacokinetics and outcome of children and young adults with osteosarcoma. Cancer100, 1724–1733 (2004).
- Giacomini KM, Huang S-M, Tweedie DJ et al.; for the the International Transporter Consortium. Membrane transporters in drug development. Nat. Rev. Drug Discover.9, 215–236 (2010).
- Mutsaers HAM, van den Heuvel LB, Ringens LH et al. Uremic toxins inhibit transport by breast resistance protein and multidrug resistance protein 4 at clinically relevant concentrations. PloS One6, e18438 (2011).
- Abe T, Unno M, Onogawa T et al. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology120, 1689–1699 (2001).
- Sasaki M, Suzuki H, Aoki J, Ito K, Meier PJ, Sugiyama Y. Prediction of in vivo biliary clearance from in vitro transcellular transport of organic anions across a double-transfected Madin-Darby canine kidney II monolayer expressing both rat organic anion transporting polypeptide 4 and multidrug resistance associated protein 2. Mol. Pharmacol.66, 450–459 (2004).
- van de Steeg E, van der Kruijssen CM, Wagenaar E et al. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab. Dispos.37, 277–281 (2009).
- Hooijberg JH, Broxterman HJ, Kool M et al. Antifolate resistance mediated by the multidrug resistance proteins MRP1 and MRP2. Cancer Res.59, 2532–2535 (1999).
- Ito KI, Oleschuk CJ, Westlake C, Vasa MZ, Deeley RG, Cole SPC. Mutation of Trp1254 in the multispecific organic anion transporter multidrug resistance protein 2 (MRP2) (ABCC2), alters substrate specificity and results in loss of methotrexate transport activity. J. Biol. Chem.276, 38108–38114 (2001).
- Hulo JS, Villard E, Maguy A et al. A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet. Genomics15, 277–285 (2005).
- Chen ZC, Lee K, Walther S et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system. Cancer Res.62, 3144–3150 (2002).
- Kool M, van der Linden M, de Haas M et al. MRP3, an organic anion transporter able to transport anti-cancer drugs. Proc. Natl Acad. Sci. USA96, 6914–6919 (1999).
- Breedveld P, Zelcer N, Pluim D et al. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug–drug interactions. Cancer Res.64, 5804–5811 (2004).
- Cha SH, Sekine T, Fukushima JI et al. Identification and characterization of human organic anion transporter 3 expressing predominantly in the kidney. Mol. Pharmacol.59, 1277–1286 (2001).
- Takeda M, Khamdang S, Narikawa S et al. Characterization of methotrexate transport and its drug interactions with human organic anion transporters. J. Pharmacol. Exp. Ther.302, 666–671 (2002).
- Nozaki Y, Kusuhara H, Endou H, Sugiyama Y. Quantitative evaluation of the drug–drug interactions between methotrexate and nonsteroidal anti-inflammatory drugs in the renal uptake process based on the contribution of organic anion transporters and reduced folate carrier. J. Pharmacol. Exp. Ther.309, 226–234 (2004).
- Richelmann RP, Tannock IF, Wang L, Saad ED, Taback NA, Krzyzanowska MK. Potential drug interactions and duplicate prescriptions among cancer patients. J. Natl Cancer Inst.99, 592–600 (2007).
- Lemachatti J, Levêque D, Beretz L, Bergerat JP. Potential pharmacokinetic interactions affecting antitumour drug disposition in cancer patients. Anticancer Res.29, 4741–4744 (2009).
- Benet L, Hoerner BA. Changes in plasma protein binding have little clinical relevance. Clin. Pharmacol. Ther.71, 115–121 (2002).
- Bourré-Tessier J, Haraoui B. Methotrexate drug interactions in the treatment of rheumatoid arthritis: a systematic review. J. Rheumatol.37, 1416–1421 (2010).
- Thyss A, Milano G, Kubar J, Namer M, Schneider M. Clinical and pharmacokinetic evidence of a life-threatening interaction between methotrexate and ketoprofen. Lancet1, 256–258 (1986).
- Nozaki Y, Kusuhara H, Kondo T et al. Species differences in the inhibitory effect of nonsteroidal anti-inflammatory drugs on the uptake of methotrexate by human kidney slices. J. Pharmacol. Exp. Ther.322, 1162–1170 (2007).
- El-Sheikh AA, van den Heuvel JJ, Koenderink JB, Russel FG. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP)2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther.320, 229–235 (2007).
- Dean R, Nachman J, Lorenzana AN. Possible methotrexate-mezlocillin interaction. Am. J. Pediatr. Hematol. Oncol.14, 88–89 (1992).
- Ronchera CL, Hernandez T, Peris JE et al. Pharmacokinetic interaction between high-dose methotrexate and amoxycillin. Ther. Drug Monit.15, 375–379 (1993).
- Yamamoto K, Sawada Y, Matsushita Y, Moriwaki K, Bessho F, Iga T. Delayed elimination of methotrexate associated with piperacillin administration. Ann. Pharmacother.31, 1261–1262 (1997).
- Zarychanski R, Wlodarczyk K, Ariano R, Bow E. Pharmacokinetic interaction between methotrexate and piperacillin/tazobactam resulting in prolonged toxic concentrations of methotrexate. J. Antimicrob. Chemother.58, 228–230 (2006).
- de Miguel D, Garcia-Suarez J, Martin Y, Gil-Fernandez JJ, Burgaleta C. Severe acute renal failure following high-dose methotrexate therapy in adults with haematological malignancies: a significant number result from unrecognized co-administration of several drugs. Nephrol. Dial. Transplant23, 3762–3766 (2008).
- Titier K, Lagrange F, Péhourcq F, Moore N, Molimard M. Pharmacokinetic interaction between high-dose methotrexate and oxacillin. Ther. Drug Monit.24, 570–572 (2002).
- Dalle J-H, Auvrignon A, Vassal G, Leverger G. Interaction between methotrexate and ciprofloxacin. J. Pediatr. Hematol. Oncol.24, 321–322 (2002).
- Blum R, Seymour JF, Toner G. Significant impairment of high-dose methotrexate clearance following vancomycin administration in the absence of overt renal impairment. Ann. Oncol.13, 327–330 (2002).
- Thyss A, Milano G, Renée N, Cassuto-Viguier E, Jambou P, Soler C. Severe interaction between methotrexate and a macrolide-like antibiotic. J. Natl Cancer Inst.85, 582–583 (1993).
- Shamash J, Joel S, Lundholm L, Millard L, Oliver T. High-dose methotrexate clearance following prior vancomycin administration: no significant interaction in the absence of overt renal impairment. Ann. Oncol.43, 169–170 (2003).
- Hazlewood KA, Brouse SD, Pitcher WD, Hall RG. Vancomycin-associated nephrotoxicity: grave concern or death by character assassination. Am. J. Med.123, 182.e1–182.e7 (2010).
- Seithel A, Eberl S, Singer K et al. The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3. Drug Metab. Dispos.35, 779–786 (2007).
- Reid T, Yuen A, Catolico M, Carlson RW. Impact of omeprazole on the plasma clearance of methotrexate. Cancer Chemother. Pharmacol.33, 82–84 (1993).
- Whelan J, Hoare D, Leonard P. Omeprazole does not alter plasma methotrexate. Cancer Chemother. Pharmacol.33, 88–89 (1999).
- Beorlegui B, Aldaz A, Ortega A, Aquerreta I, Sierrasesumega L, Giraldez J. Potential interaction between methotrexate and omeprazole. Ann. Pharmacother.34, 1024–1027 (2000).
- Tröger U, Stötzel B, Martens-Lobenhoffer J, Gollnick H, Meter FP. Drug points: severe myalgia from an interaction between treatments with pantoprazole and methotrexate. Br. Med. J.324, 1497 (2002).
- Joerger M, Huitema A, Van den Bongard H et al. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. Br. J. Clin. Pharmacol.62, 71–80 (2005).
- Bauters TGM, Verlooy J, Robays H, Laureys G. Interaction between methotrexate and omeprazole in an adolescent with leukemia: a case report. Pharm. World Sci.30, 316–318 (2008).
- Suzuki K, Doki K, Homma M et al. Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br. J. Clin. Pharmacol.67, 44–49 (2009).
- Santucci R, Levêque D, Lescoute A, Kemmel V, Herbrecht R. Delayed elimination of methotrexate associated with co-administration of proton pump inhibitors. Anticancer Res.30, 3807–3810 (2010).
- Santucci R, Levêque D, Kemmel V et al. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Anticancer Res.30, 963–966 (2010).
- Aherne GW, Piall E, Marks V, Mould G, White WF. Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br. J. Med.1, 1097–1099 (1978).
- Shitara Y, Hirano M, Sato H, Sugiyama Y. Gemfibrozil and its glucuronide inhibit the organic anion transporting polypeptide 2 (OATP2/OATP1B1:SLC21A6) mediated hepatic uptake and CYP2C8-mediated metabolism of cerivastatin: analysis of the mechanism of the clinically relevant drug–drug interaction between cerivastatin and gemfibrozil. J. Pharmacol. Exp. Ther.311, 228–236 (2004).
- Watanabe T, Kusuhara H, Watanabe T et al. Prediction of the overall renal tubular secretion and hepatic clearance of anionic drugs and a renal drug–drug interaction involving organic anion transporter 3 in humans by in vitro uptake experiments. Drug Metab. Dispos.39, 1031–1038 (2011).
- van Hest RM, Schnog JB, van’t Veer MB, Cornelissen JJ. Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated by imatinib. Am. J. Hematol.83, 757–758 (2008).
- Scholler J, Levêque D. Molecular pharmacokinetic determinants of anticancer kinase inhibitors in humans. Oncol. Rev.5, 77–92 (2011).
- Relling MV, Pui CH, Sandlund JT et al. Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet356, 285–290 (2000).
- Riva M, Landonio G, Defanti CA, Siena S. The effect of anticonvulsant drugs on blood levels of methotrexate. J. Neurooncol.48, 249–250 (2000).
- Oscarson M, Zanger UM, Rifki OF, Klein K, Eichelbaum M, Meyer UA. Transcriptional profiling of genes induced in the livers of patients treated by carbamazepine. Clin. Pharmacol. Ther.80, 440–456 (2006).